Vanguard Global Advisers
BBIO icon

Vanguard Global Advisers’s BridgeBio Pharma BBIO Stock Holding History

Vanguard Global Advisers’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.56M Sell
74,692
-412
-0.5% -$28.9K ﹤0.01% 757
2026
Q1 		$5.58M Buy
+75,104
New +$5.44M ﹤0.01% 730

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Vanguard Global Advisers's BBIO Position: Q2 2026 in Review

Vanguard Global Advisers reduced its BridgeBio Pharma (BBIO) stake by 0.55% in Q2 2026, selling an estimated $28.9K and leaving 74,692 shares worth $5.56M. The position accounts for ﹤0.01% of the portfolio, ranked #757.

Vanguard Global Advisers first reported a position in BBIO in Q1 2026 and has held it in 2 quarters since. The position peaked at $5.58M in Q1 2026. 464 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Vanguard Global Advisers held 74,692 shares of BridgeBio Pharma worth $5.56M as of Q2 2026.
  • Vanguard Global Advisers sold 412 BridgeBio Pharma shares in Q2 2026, an estimated $28.9K.
  • BridgeBio Pharma made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #757 holding.
  • Vanguard Global Advisers first reported a position in BridgeBio Pharma in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Global Advisers's BridgeBio Pharma position peaked at $5.58M in Q1 2026.
  • 464 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.